Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 361

1.

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.

Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, Brandt BH, Dittmar T.

J Pathol. 2012 Jun;227(2):234-44. doi: 10.1002/path.3991. Epub 2012 Mar 21. Erratum in: J Pathol. 2013 May;230(1):e1.

PMID:
22262199
[PubMed - indexed for MEDLINE]
2.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

PMID:
24044505
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells.

Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jücker M.

Cell Signal. 2011 Dec;23(12):1952-60. doi: 10.1016/j.cellsig.2011.07.003. Epub 2011 Jul 12.

PMID:
21777670
[PubMed - indexed for MEDLINE]
4.

Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.

Paris L, Cecchetti S, Spadaro F, Abalsamo L, Lugini L, Pisanu ME, Iorio E, Natali PG, Ramoni C, Podo F.

Breast Cancer Res. 2010;12(3):R27. doi: 10.1186/bcr2575. Epub 2010 May 12.

PMID:
20462431
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.

Tanizaki J, Okamoto I, Sakai K, Nakagawa K.

Br J Cancer. 2011 Sep 6;105(6):807-13. doi: 10.1038/bjc.2011.322. Epub 2011 Aug 16.

PMID:
21847121
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.

Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R.

Int J Cancer. 2008 Dec 15;123(12):2939-49. doi: 10.1002/ijc.23902.

PMID:
18803287
[PubMed - indexed for MEDLINE]
7.
8.

Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.

Wu Y, Zhang Y, Wang M, Li Q, Qu Z, Shi V, Kraft P, Kim S, Gao Y, Pak J, Youngster S, Horak ID, Greenberger LM.

Mol Cancer Ther. 2013 Apr;12(4):427-37. doi: 10.1158/1535-7163.MCT-12-0838. Epub 2013 Feb 8.

PMID:
23395887
[PubMed - indexed for MEDLINE]
Free Article
9.

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.

Choi BK, Fan X, Deng H, Zhang N, An Z.

Cancer Med. 2012 Aug;1(1):28-38. doi: 10.1002/cam4.10. Epub 2012 Jul 15.

PMID:
23342251
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM.

Cancer Res. 2008 Jul 15;68(14):5878-87. doi: 10.1158/0008-5472.CAN-08-0380.

PMID:
18632642
[PubMed - indexed for MEDLINE]
Free Article
11.

Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.

Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zänker KS, Brandt BH.

FASEB J. 2002 Nov;16(13):1823-5. Epub 2002 Sep 19.

PMID:
12354693
[PubMed - indexed for MEDLINE]
Free Article
12.

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, Vicentini C, Bologna M.

Thromb Haemost. 2005 May;93(5):964-75.

PMID:
15886816
[PubMed - indexed for MEDLINE]
13.

Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.

Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N.

Cancer Res. 2005 Dec 1;65(23):11018-25.

PMID:
16322251
[PubMed - indexed for MEDLINE]
Free Article
14.

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.

Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.

PMID:
17206155
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.

Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, Kuwano M, Ono M.

Cancer Res. 2005 May 15;65(10):4253-60.

PMID:
15899817
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.

Shankaran H, Zhang Y, Tan Y, Resat H.

PLoS Comput Biol. 2013;9(8):e1003201. doi: 10.1371/journal.pcbi.1003201. Epub 2013 Aug 22.

PMID:
23990774
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.

Yao W, Feng D, Bian W, Yang L, Li Y, Yang Z, Xiong Y, Zheng J, Zhai R, He J.

Amino Acids. 2012 Nov;43(5):2027-35. doi: 10.1007/s00726-012-1277-z. Epub 2012 Apr 4.

PMID:
22476347
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.

Kim S, Han J, Shin I, Kil WH, Lee JE, Nam SJ.

Exp Mol Med. 2012 Aug 31;44(8):473-82. doi: 10.3858/emm.2012.44.8.054.

PMID:
22627808
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.

Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT.

Cancer Res. 2007 Aug 1;67(15):7256-65.

PMID:
17671194
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk